Grifols, S.A. - Product Pipeline Review - 2014

Published: Apr, 2014 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Grifols, S.A. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Grifols, S.A. - Product Pipeline Review - 2014', provides an overview of the Grifols, S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Grifols, S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Grifols, S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Grifols, S.A.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Grifols, S.A.'s pipeline products

Reasons to buy

- Evaluate Grifols, S.A.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Grifols, S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Grifols, S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Grifols, S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Grifols, S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Grifols, S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Grifols, S.A. Snapshot 5
Grifols, S.A. Overview 5
Key Information 5
Key Facts 5
Grifols, S.A. - Research and Development Overview 6
Key Therapeutic Areas 6
Grifols, S.A. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Grifols, S.A. - Pipeline Products Glance 11
Grifols, S.A. - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Grifols, S.A. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Grifols, S.A. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Grifols, S.A. - Drug Profiles 15
ARD-3150 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
immune globulin (human) 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
albumin (human) 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Human Plasmin 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Recombinant A1PI 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ARD-3100 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
fibrinogen 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Human Coagulation Factor-VIII 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Recombinant Plasmin 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Grifols, S.A. - Pipeline Analysis 28
Grifols, S.A. - Pipeline Products by Target 28
Grifols, S.A. - Pipeline Products by Route of Administration 30
Grifols, S.A. - Pipeline Products by Molecule Type 31
Grifols, S.A. - Pipeline Products by Mechanism of Action 32
Grifols, S.A. - Recent Pipeline Updates 34
Grifols, S.A. - Dormant Projects 40
Grifols, S.A. - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Grifols, S.A., Key Information 5
Grifols, S.A., Key Facts 5
Grifols, S.A. - Pipeline by Indication, 2014 8
Grifols, S.A. - Pipeline by Stage of Development, 2014 9
Grifols, S.A. - Monotherapy Products in Pipeline, 2014 10
Grifols, S.A. - Phase III, 2014 11
Grifols, S.A. - Phase II, 2014 12
Grifols, S.A. - Phase I, 2014 13
Grifols, S.A. - Preclinical, 2014 14
Grifols, S.A. - Pipeline by Target, 2014 29
Grifols, S.A. - Pipeline by Route of Administration, 2014 30
Grifols, S.A. - Pipeline by Molecule Type, 2014 31
Grifols, S.A. - Pipeline Products by Mechanism of Action, 2014 33
Grifols, S.A. - Recent Pipeline Updates, 2014 34
Grifols, S.A. - Dormant Developmental Projects,2014 40
Grifols, S.A., Other Locations 41
Grifols, S.A., Subsidiaries 42